Trial Profile
Phase II trial of AGS 003 for the treatment of non-clear cell metastatic renal cell carcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2015
Price :
$35
*
At a glance
- Drugs Rocapuldencel T (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 May 2014 New trial record
- 13 May 2014 Argos Therapeutics intends to devote its cash, cash equivalents and short term investments to fund its planned phase 2 clinical trial of AGS 003 in non-clear cell mRCC.